Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
Clément BerthelotPaul HuchedéAdrien Bertrand-ChapelPierre-Aurélien BeuriatPierre LeblondMarie CastetsPublished in: International journal of molecular sciences (2024)
The BMP pathway is one of the major signaling pathways in embryonic development, ontogeny and homeostasis, identified many years ago by pioneers in developmental biology. Evidence of the deregulation of its activity has also emerged in many cancers, with complex and sometimes opposing effects. Recently, its role has been suspected in Diffuse Midline Gliomas (DMG), among which Diffuse Intrinsic Pontine Gliomas (DIPG) are one of the most complex challenges in pediatric oncology. Genomic sequencing has led to understanding part of their molecular etiology, with the identification of histone H3 mutations in a large proportion of patients. The epigenetic remodeling associated with these genetic alterations has also been precisely described, creating a permissive context for oncogenic transcriptional program activation. This review aims to describe the new findings about the involvement of BMP pathway activation in these tumors, placing their appearance in a developmental context. Targeting the oncogenic synergy resulting from this pathway activation in an H3K27M context could offer new therapeutic perspectives based on targeting treatment-resistant cell states.
Keyphrases
- high grade
- low grade
- end stage renal disease
- single cell
- transcription factor
- mesenchymal stem cells
- gene expression
- ejection fraction
- chronic kidney disease
- signaling pathway
- bone regeneration
- newly diagnosed
- dna methylation
- palliative care
- cancer therapy
- prognostic factors
- genome wide
- cell therapy
- quality improvement
- copy number
- bone mineral density
- cell proliferation
- drug delivery
- oxidative stress
- bone loss
- postmenopausal women
- body composition
- patient reported
- induced apoptosis